Alemtuzumab for the treatment of multiple sclerosis.
作者信息
Willis Mark D, Robertson Neil P
机构信息
Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales, Heath Park, Cardiff, UK.
出版信息
Ther Clin Risk Manag. 2015 Mar 31;11:525-34. doi: 10.2147/TCRM.S80112. eCollection 2015.
Abstract
摘要
相似文献
1
Alemtuzumab for the treatment of multiple sclerosis.阿仑单抗用于治疗多发性硬化症。
Ther Clin Risk Manag. 2015 Mar 31;11:525-34. doi: 10.2147/TCRM.S80112. eCollection 2015.
2
Low vitamin D levels do not predict risk of autoimmune disease following alemtuzumab treatment for multiple sclerosis.低维生素 D 水平不能预测多发性硬化症用阿仑单抗治疗后的自身免疫性疾病风险。
Mult Scler Relat Disord. 2022 Mar;59:103511. doi: 10.1016/j.msard.2022.103511. Epub 2022 Jan 10.
3
B cell depletion therapy resulting in sustained remission of severe autoimmune complications following Alemtuzumab treatment of Multiple Sclerosis.阿仑单抗治疗多发性硬化症导致 B 细胞耗竭治疗后严重自身免疫并发症持续缓解。
Mult Scler Relat Disord. 2019 Oct;35:100-103. doi: 10.1016/j.msard.2019.07.016. Epub 2019 Jul 20.
4
Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.在使用阿仑单抗治疗多发性硬化症后，发生危及生命的自身免疫性温性溶血性贫血。
Mult Scler. 2018 May;24(6):811-813. doi: 10.1177/1352458517729766. Epub 2018 Jan 23.
5
Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.在多发性硬化症患者中使用阿仑单抗治疗后的自身免疫性肾病的发病率、处理方法和结局。
Mult Scler. 2019 Aug;25(9):1273-1288. doi: 10.1177/1352458519841829. Epub 2019 Apr 15.
6
Autoimmune encephalitis following alemtuzumab treatment of multiple sclerosis.多发性硬化症用阿仑单抗治疗后出现自身免疫性脑炎。
Mult Scler Relat Disord. 2019 Feb;28:31-33. doi: 10.1016/j.msard.2018.12.004. Epub 2018 Dec 3.
7
Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: A case report.获得性血友病 A 作为多发性硬化症阿仑单抗治疗后的继发自身免疫性疾病：一例报告。
Mult Scler Relat Disord. 2019 Jan;27:403-405. doi: 10.1016/j.msard.2018.11.029. Epub 2018 Nov 29.
8
Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.在使用阿仑单抗治疗多发性硬化症期间同时出现早期严重自身免疫性溶血性贫血和蛋白尿。
Mult Scler. 2018 May;24(6):813-815. doi: 10.1177/1352458517743093. Epub 2018 Jan 23.
9
Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis.多发性硬化症用阿仑单抗治疗后发生自身免疫性甲状腺疾病。
Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419843690. doi: 10.1177/2058738419843690.
10
Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies.在阿仑单抗治疗多发性硬化症（CARE-MS）研究中，自身免疫性甲状腺事件患者的内分泌及多发性硬化症相关转归
Mult Scler J Exp Transl Clin. 2023 Jan 3;9(1):20552173221142741. doi: 10.1177/20552173221142741. eCollection 2023 Jan-Mar.
引用本文的文献
1
'Immune reset plus': the case for combining immunotherapies to maintain self-tolerance in autoimmune diseases.“免疫重置加疗法”：联合免疫疗法在自身免疫性疾病中维持自我耐受的理由。
Front Immunol. 2025 Jul 23;16:1634090. doi: 10.3389/fimmu.2025.1634090. eCollection 2025.
2
Alemtuzumab treatment for multiple sclerosis in Austria: An observational long-term outcome study.奥天时的阿仑单抗医治多发性软化症：一项观测性长时刻结局研讨。
Ann Clin Transl Neurol. 2024 Jun;11(6):1442-1455. doi: 10.1002/acn3.52056. Epub 2024 May 7.
3
Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature.神经免疫治疗在 COVID-19 时代——在文献中寻找共识。
Nat Rev Neurol. 2020 Sep;16(9):493-505. doi: 10.1038/s41582-020-0385-8. Epub 2020 Jul 8.
4
Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis.阿仑单抗的临床药理学：一种抗 CD52 免疫调节剂在多发性硬化症中的应用。
Clin Exp Immunol. 2018 Dec;194(3):295-314. doi: 10.1111/cei.13208. Epub 2018 Oct 1.
5
Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.用阿仑单抗治疗的多发性硬化症患者免疫性血小板减少症的管理：一项比利时共识。
Acta Neurol Belg. 2018 Mar;118(1):7-11. doi: 10.1007/s13760-018-0882-3. Epub 2018 Jan 27.
6
Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus.多发性硬化症中与阿仑单抗治疗相关的不良肾脏事件的管理：一项比利时共识。
Acta Neurol Belg. 2018 Jun;118(2):143-151. doi: 10.1007/s13760-017-0864-x. Epub 2017 Nov 30.
7
Alemtuzumab for Multiple Sclerosis.阿仑单抗治疗多发性硬化症
Curr Neurol Neurosci Rep. 2016 Sep;16(9):84. doi: 10.1007/s11910-016-0685-y.
8
Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS).在德国开展的一项关于阿仑单抗治疗多发性硬化症患者的安全性、有效性、生活质量、认知、健康相关及工作能力数据的非干预性研究的基本原理、设计与方法（TREAT-MS研究）
BMC Neurol. 2016 Jul 19;16:109. doi: 10.1186/s12883-016-0629-9.
9
Multiple sclerosis--new treatment modalities.多发性硬化症——新的治疗方式
Indian J Med Res. 2015 Dec;142(6):647-54. doi: 10.4103/0971-5916.174543.
10
Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.复发缓解型多发性硬化症的治疗进展与算法。
Neurotherapeutics. 2016 Jan;13(1):47-57. doi: 10.1007/s13311-015-0412-4.
本文引用的文献
1
2014 Joint ACTRIMS-ECTRIMS Meeting (MSBoston 2014): Oral Presentations.2014年美国多发性硬化症治疗与研究委员会（ACTRIMS）和欧洲多发性硬化症治疗与研究委员会（ECTRIMS）联合会议（2014年波士顿多发性硬化症会议）：口头报告
Mult Scler. 2014 Sep;20(1 Suppl):14-66. doi: 10.1177/1352458514546076.
2
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy.阿仑单抗治疗多发性硬化症：长期安全性和疗效。
J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):208-15. doi: 10.1136/jnnp-2014-307721. Epub 2014 May 21.
3
Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity.阿仑单抗治疗后淋巴细胞加速恢复不能预测多发性硬化症的活动情况。
Neurology. 2014 Jun 17;82(24):2158-64. doi: 10.1212/WNL.0000000000000520. Epub 2014 May 16.
4
Immune reconstitution and treatment response in multiple sclerosis following alemtuzumab.阿仑单抗治疗后多发性硬化症的免疫重建与治疗反应
Neurology. 2014 Jun 17;82(24):2150-1. doi: 10.1212/WNL.0000000000000530. Epub 2014 May 16.
5
Product licences for alemtuzumab and multiple sclerosis.阿仑单抗与多发性硬化症的产品许可证。
Lancet. 2014 Mar 8;383(9920):867-8. doi: 10.1016/S0140-6736(14)60440-2.
6
Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation.淋巴细胞耗竭后人体发生自身免疫是由同种型 T 细胞的自身反应性增殖引起的。
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20200-5. doi: 10.1073/pnas.1313654110. Epub 2013 Nov 26.
7
Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects.精细定位多发性硬化症中主要组织相容性复合体的遗传关联：HLA 和非 HLA 效应。
PLoS Genet. 2013 Nov;9(11):e1003926. doi: 10.1371/journal.pgen.1003926. Epub 2013 Nov 21.
8
Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.在复发缓解型多发性硬化症患者中，用阿仑单抗（抗 CD52 单克隆抗体）进行免疫耗竭治疗后，T 细胞亚群的差异重建。
J Immunol. 2013 Dec 15;191(12):5867-74. doi: 10.4049/jimmunol.1301926. Epub 2013 Nov 6.
9
Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.在一项复发缓解型多发性硬化症患者的 2 期临床试验中，阿仑单抗相关甲状腺功能紊乱。
J Clin Endocrinol Metab. 2014 Jan;99(1):80-9. doi: 10.1210/jc.2013-2201. Epub 2013 Dec 20.
10
Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.阿仑单抗治疗对体外人调节性 T 细胞存活和功能的影响。
Immunology. 2014 Jan;141(1):123-31. doi: 10.1111/imm.12178.
Zotero 插件